Chinyere Okpara

5PUBLICATIONS
77CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Mar 12, 2026
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study.

Lisa Licitra, Makoto Tahara, Kevin Harrington

|Feb 26, 2026
Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study.

Mariano Ponz-Sarvisé, Sun Young Rha, Carlos A Gomez-Roca

|Nov 26, 2024
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.

Christian Marth, Richard G Moore, Mariusz Bidziński

|Jan 16, 2024
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.

Robert J Motzer, Camillo Porta, Masatoshi Eto

|Apr 14, 2023
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775.

Vicky Makker, Nicoletta Colombo, Antonio Casado Herráez

Pageof 1

Frequent Collaborators

3 joint publications

Jodi McKenzie

2 joint publications

Corina E Dutcus

2 joint publications

Sun Young Rha

2 joint publications

Vicky Makker